We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 24% Below Their Intrinsic Value Estimate
Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50?
RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
RBC Capital analyst Brian Abrahams maintains $Xenon Pharmaceuticals(XENE.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 0.0
Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 25% Above Its Share Price